Study protocol for developing a patient-reported outcome measure for infection screening in hematological patients with secondary immunodeficiency.
Jens Lehmann, Jan-Paul Bohn, Claudia Seidl...
https://pubmed.ncbi.nlm.nih.gov/41162921/Actively Recruiting
Led by Medical University Innsbruck · Updated on 2025-02-12
120
Participants Needed
5
Research Sites
N/A
Total Duration
Researchers are evaluating a new patient-reported outcome PRO tool designed to detect infections in adults with chronic lymphocytic leukemia CLL or multiple myeloma MM who have secondary immunodeficiency SID. The study aims to improve infection detection and track changes in quality of life over time in this vulnerable group. This observational study is conducted at multiple centers in Germany and Austria and involves patients starting anticancer therapy. Participants will use a mobile app daily to complete electronic PRO questionnaires about infection-related symptoms. Quality of life questionnaires are completed every 1.5 months. Study visits occur every three months to document clinical data such as treatment updates, disease status, and infection history. The app was developed based on a tested software platform and includes features like push reminders to encourage daily symptom reporting. During the year-long participation, researchers will monitor the accuracy of the PRO tool in detecting infections, evaluate adherence to daily reporting, and assess quality of life using validated instruments. Clinical data will be collected and infections documented during quarterly visits. Patient safety and confidentiality are maintained according to ethical standards throughout the study.
CONDITIONS
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
J
Jens Lehmann, Ph.D.
J
Jan-Paul Bohn, Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Medical University Innsbruck
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - Up to 1 year (365 days)
Participants complete daily electronic patient-reported outcome (ePRO) symptom assessments via a mobile app to monitor infection-related symptoms. Clinicians document infections and relevant clinical data during quarterly study visits.
Daily symptom reporting via app and visits every 3 months
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Jens Lehmann, Jan-Paul Bohn, Claudia Seidl...
https://pubmed.ncbi.nlm.nih.gov/41162921/Medical University Innsbruck
Lead Sponsor